Mitsubishi UFJ Trust & Banking’s Catalyst Pharmaceutical CPRX Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$261K	Buy	+10,539	New	+$251K	﹤0.01%	1044

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Mitsubishi UFJ Trust & Banking's CPRX Position: Q1 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 10,539 shares worth $261K. The stake represents ﹤0.01% of the portfolio and ranks #1044 among its holdings.

380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Mitsubishi UFJ Trust & Banking held 10,539 shares of Catalyst Pharmaceutical worth $261K as of Q1 2026.
Catalyst Pharmaceutical was a new Mitsubishi UFJ Trust & Banking position in Q1 2026.
Catalyst Pharmaceutical made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q1 2026, its #1044 holding.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q1 2026, filed 12 May 2026.